01—Abstract
Summary
Summary of the 8-K filed February 4, 2025. Cited figures are marked; the original filing is the authoritative source.
Merck & Co. (MRK) reported fourth-quarter and full-year 2024 results on February 4, 2025, showing strong top-line momentum led by KEYTRUDA.
Fourth-quarter worldwide sales rose 7% to $15.6 billiona (9% excluding foreign exchange), and full-year sales grew 7% to $64.2 billion (10% ex-FX). KEYTRUDA was the standout, with full-year sales up 18% to $29.5 billion, while GARDASIL/GARDASIL 9 declined 3% to $8.6 billion, driven largely by weaker demand in China. WINREVAIR launched in the second quarter of 2024 and reached $419 million in its first partial year, and Animal Health grew 4% to $5.9 billion.
GAAP results were distorted by business development charges. Full-year GAAP EPS was $6.74b and non-GAAP EPS was $7.65, both including a net $1.28 per-share charge tied to licensing deals and collaborations. Fourth-quarter GAAP EPS was $1.48 and non-GAAP EPS was $1.72, including a $0.23 charge tied to the LaNova and Hansoh agreements.
Year-over-year comparisons are heavily affected by the prior year's large charges and the 2023 Zetia settlement, so the non-GAAP figures are the more useful measure of underlying performance. Margin expansion was notable: non-GAAP gross margin reached 80.8% in both the fourth quarter and full year, reflecting favorable product mix, including lower royalty rates on KEYTRUDA and GARDASIL. For 2025, Merck guided to sales of $64.1 billion to $65.6 billionc and non-GAAP EPS of $8.88 to $9.03.
The outlook includes a roughly $0.09d per-share one-time charge for a $300 million LaNova milestone payment, and it reflects a temporary pause in GARDASIL shipments to China starting February 2025 through at least mid-year. The guidance also excludes any significant new business development deals, consistent with past practice. Pipeline news included positive ZENITH results for WINREVAIR (stopped early for overwhelming efficacy), positive Phase 3 data for subcutaneous pembrolizumab, and an FDA BLA acceptance for clesrovimab with a June 10, 2025 PDUFA date.
02—Key points
Key Highlights
- Q4 2024 sales rose 7% to $15.6 billion (9% ex-FX); full-year sales rose 7% to $64.2 billion (10% ex-FX).
- KEYTRUDA full-year sales grew 18% to $29.5 billion (22% ex-FX), with Q4 sales of $7.8 billion, up 19%.
- GAAP EPS was $1.48 in Q4 and $6.74 for the full year; non-GAAP EPS was $1.72 in Q4 and $7.65 for the full year, both burdened by business development charges ($0.23 in Q4; $1.28 for the year).
- Non-GAAP gross margin expanded to 80.8% in both Q4 and full-year 2024, aided by product mix and lower KEYTRUDA and GARDASIL royalty rates.
- WINREVAIR generated $419 million in its first partial year of launch, and WELIREG sales more than doubled to $509 million.
- GARDASIL/GARDASIL 9 sales fell 3% for the year to $8.6 billion, with Q4 down 17%, largely due to weaker demand in China.
- 2025 guidance: sales of $64.1–65.6 billion and non-GAAP EPS of $8.88–9.03, including a ~$0.09 one-time charge for a $300 million LaNova milestone payment and a planned GARDASIL shipment pause into China through mid-2025.
03—Questions
Frequently Asked Questions
Why does GAAP EPS differ from non-GAAP EPS, and which should investors focus on?
The gap comes mainly from acquisition- and divestiture-related costs (including intangible asset amortization), restructuring costs, and equity investment gains or losses. For 2024, these items total about $0.91 per share. Non-GAAP EPS of $7.65 is the figure management uses to assess underlying performance and to set its guidance, while GAAP EPS of $6.74 is the audited measure. Investors should consider both, with the reconciliation tables providing the detail.
What is driving the 2025 GARDASIL pause in China, and how material is it?
Merck decided to temporarily pause GARDASIL/GARDASIL 9 shipments into China starting February 2025 through at least mid-year, after China sales fell sharply in 2024. The company said the pause is reflected in its 2025 sales range. The filing does not quantify the exact impact, but GARDASIL generated $8.6 billion globally in 2024, and China was a meaningful share of the decline, so the pause is a notable headwind to the vaccine franchise.
How sustainable is KEYTRUDA's growth, and what risks come with it?
KEYTRUDA grew 18% in 2024 to $29.5 billion, supported by metastatic and earlier-stage indications and expanding uptake in bladder, endometrial, and triple-negative breast cancer. The positive subcutaneous pembrolizumab Phase 3 data point to a potential patient-experience upgrade that could extend its franchise. Risks include the eventual loss of exclusivity and pricing pressure. The filing also notes that royalty rates on KEYTRUDA are lower, which is currently helping margins.
Are the 2025 guidance figures expected to include new acquisitions or licensing deals?
No. Merck states that its outlook does not assume any additional significant business development transactions, consistent with its past practice. Any new deals would likely add incremental charges to GAAP and non-GAAP results, as seen in 2024 with the LaNova and Hansoh agreements, so future guidance revisions could occur if the company completes material transactions.
What are the key pipeline catalysts following this report?
The most near-term catalyst is the FDA decision on clesrovimab, an RSV prophylaxis for infants, with a PDUFA date of June 10, 2025. Other notable items include WINREVAIR's ZENITH and HYPERION Phase 3 trials, both stopped early for efficacy, which could support expanded labeling, and the EU decision on CAPVAXIVE expected in Q2 2025. Investors should also watch sac-TMT, which received FDA Breakthrough Therapy designation for EGFR-mutated NSCLC.
04—Continue